Securin identifies a subgroup of patients with poor outcome in rectal cancer treated with long-course (chemo)radiotherapy

References

• Improved survival with preoperative radiotherapy in resectable rectal cancer. Swedish rectal cancer trial. N Engl J Med 1997;336:980–7.
   PubMed Web of Science ®Google Scholar
• Randomised trial of surgery alone versus radiotherapy followed by surgery for potentially operable locally advanced rectal cancer. Medical Research Council Rectal Cancer Working Party. Lancet 1996;348:1605–10.
   PubMedGoogle Scholar
• Debucquoy A, Goethals L, Libbrecht L, Perneel C, Geboes K, Ectors N, . Molecular and clinico-pathological markers in rectal cancer: A tissue micro-array study. Int J Colorectal Dis 2009;24:129–38.
   PubMed Web of Science ®Google Scholar
• Brown DC, GatterKC. Ki67 protein: The immaculate deception? Histopathology 2002;40:2–11.
   PubMed Web of Science ®Google Scholar
• Zou H, McGarry TJ, Bernal T, Kirschner MW. Identification of a vertebrate sister-chromatid separation inhibitor involved in transformation and tumorigenesis. Science 1999;285:418–22.
   PubMed Web of Science ®Google Scholar
• Ramos-Morales F, Domínquez A, Romero F, Luna R, Multon MC, Pintor-Toro JA, . Cell cycle regulated expression and phosphorylation of hpttg proto-oncogene product. Oncogene 2002;19:403–9.
   Web of Science ®Google Scholar
• Gerdes J, Lemke H, Baisch H, Wacker HH, Schwab U, Stein H. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 1984;133:1710–5.
   PubMed Web of Science ®Google Scholar
• Pei L, Melmed S. Isolation and characterization of pituitary tumor-transforming gene (PTTG). Mol Endocrinol 1997;11:433–41.
   PubMed Web of Science ®Google Scholar
• McCabe CJ, Boelaert K, Tannahill LA, Heaney AP, Stratford AL, Khaira JS, . Vascular endothelial growth factor, its receptor KDR/Flk-1, and pituitary tumor transforming gene in pituitary tumors. J Clin Endocrinol Metab 2002;87:4238–44.
   PubMed Web of Science ®Google Scholar
• Malik MT, Kakar SS. Regulation of angiogenesis and invasion by human Pituitary tumor transforming gene (PTTG) through increased expression and secretion of matrix metalloproteinase-2 (MMP-2). Mol Cancer 2006;5:61.
   PubMed Web of Science ®Google Scholar
• Salehi F, Kovacs K, Scheithauer BW, Lloyd RV, Cusimano M. Pituitary-tumor transforming gene in endocrine and other neoplasms: A review and update. Endocr Relat Cancer 2008;15:721–43.
   PubMed Web of Science ®Google Scholar
• Heaney AP, Singson R, McCabe CJ, Nelson V, Nakashima M, Melmed S. Expression of pituitary-tumour transforming gene in colorectal tumours. Lancet 2000;355:716–9.
   PubMed Web of Science ®Google Scholar
• Kim DS, Franklyn JA, Smith VE, Stratford AL, Pemberton HN, Warfield A, . Securin induces genetic instability in colorectal cancer by inhibiting double-stranded DNA repair activity. Carcinogenesis 2007;28:749–59.
   PubMed Web of Science ®Google Scholar
• Hlubek F, Pfeiffer S, Budczies J, Spaderna S, Jung A, Kirchner T, . Securin (hPTTG1) expression is regulated by beta-catenin/TCF in human colorectal carcinoma. Br J Cancer 2006;94:1672–7.
   PubMed Web of Science ®Google Scholar
• Chiu SJ, Hsu TS, Chao JI. Expression of securin promotes colorectal cancer cell death via p53-independent pathway after radiation. Chem Biol Interact 2007;170:153–61.
   PubMed Web of Science ®Google Scholar
• Chen WS, Yu YC, Lee YJ, Chen JH, Hsu HY, Chiu SJ. Depletion of securin induces senescence after irradiation and enhances radiosensitivity in human cancer cells regardless of functional p53 expression. Int J Radiat Oncol Biol Phys 2010;77:566–74.
   Google Scholar
• Glimelius B, Påhlman L, Cervantes A. ESMO Guidelines Working Group. Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010;21(Suppl 5):v82–6.
   Google Scholar
• Korkeila E, Talvinen K, Jaakkola PM, Minn H, Syrjänen K, Sundström J, . Expression of carbonic anhydrase IX suggests poor outcome in rectal cancer. Br J Cancer 2009; 100:874–80.
   PubMed Web of Science ®Google Scholar
• Willett CG, Warland G, Hagan MP, Daly WJ, Coen J, Shellito PC, . Tumor proliferation in rectal cancer following preoperative irradiation. J Clin Oncol 1995;13:1417–24.
   PubMed Web of Science ®Google Scholar
• Filippella M, Galland F, Kujas M, Young J, Faggiano A, Lombardi G, . Pituitary tumour transforming gene (PTTG) expression correlates with the proliferative activity and recurrence status of pituitary adenomas: A clinical and immunohistochemical study. Clin Endocrinol (Oxf) 2006; 65:536–43.
   PubMed Web of Science ®Google Scholar
• Talvinen K, Tuikkala J, Nevalainen O, Rantanen A, Hirsimäki P, Sundström J, . Proliferation marker securin identifies favourable outcome in invasive ductal breast cancer. Br J Cancer 2008;99:335–40.
   PubMed Web of Science ®Google Scholar
• Waizenegger I, Giménez-Abián JF, Wernick D, Peters JM. Regulation of human separase by securin binding and autocleavage. Curr Biol 2002;12:1368–78.
   PubMed Web of Science ®Google Scholar
• Yu R, Heaney AP, Lu W, Chen J, Melmed S. Pituitary tumor transforming gene causes aneuploidy and p53-dependent and p53-independent apoptosis. J Biol Chem 2000;275:36502–5.
   PubMed Web of Science ®Google Scholar
• Fowler JF. The first James Kirk memorial lecture. What next in fractionated radiotherapy? Br J Cancer Suppl 1984;6:285–300.
   Google Scholar
• Guillem JG, Chessin DB, Cohen AM, Shia J, Mazumdar M, Enker W, . Long-term oncologic outcome following preoperative combined modality therapy and total mesorectal excision of locally advanced rectal cancer. Ann Surg 2005;241:829–36.
   PubMed Web of Science ®Google Scholar
• Korkeila E, Jaakkola PM, Syrjänen K, Pyrhönen S, Sundström J. Pronounced tumour regression after radiotherapy is associated with negative/weak glucose transporter-1 expression in rectal cancer. Anticancer Res 2011;31:311–5.
   PubMed Web of Science ®Google Scholar
• Chao JI, Liu HF. The blockage of survivin and securin expression increases the cytochalasin B-induced cell death and growth inhibition in human cancer cells. Mol Pharmacol 2006;69:154–64.
   PubMed Web of Science ®Google Scholar